Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Endocrine 1

Conditions

Carcinoma, Hepatocellular 28Carcinoma, Non-Small-Cell Lung 23Lung Neoplasms 17Biliary Tract Neoplasms 13Small Cell Lung Carcinoma 12Cholangiocarcinoma 12Triple Negative Breast Neoplasms 8Breast Neoplasms 8Neoplasms 6Neoplasm Metastasis 5Liver Neoplasms 5Urinary Bladder Neoplasms 4Stomach Neoplasms 4Carcinoma 4Pancreatic Neoplasms 3Non-Muscle Invasive Bladder Neoplasms 3Gallbladder Neoplasms 3Colorectal Neoplasms 3Adenocarcinoma Of Esophagus 3Pathologic Complete Response 2Ovarian Neoplasms 2Esophageal Neoplasms 2Endometrial Neoplasms 2Bile Duct Neoplasms 2Advanced Biliary Tract Cancer 2Adenocarcinoma of Lung 2Adenocarcinoma 2Vaccinia 1SCLC, Limited Stage 1Resectable Intrahepatic Cholangiocarcinoma 1

Interventions

Cisplatin 4Etoposide 3atezolizumab 2Drug Therapy 2Carboplatin 2tivozanib 1repotrectinib 1lutetium Lu 177 dotatate 1durvalumab 1dostarlimab 1belinostat 1Somatostatin 1Paclitaxel 1Nivolumab 1Neoadjuvant Therapy 1Magnetic Resonance Imaging 1Ipilimumab 1FOLFOXIRI protocol 1EC regimen 1DLL3 protein, human 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Carcinoma, Neuroendocrine × durvalumab × Clear all
NCT07174583 2026-01-23

A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer

IDEAYA Biosciences

Phase 1/2 Recruiting
208 enrolled
EndocrineThoracic

Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡